Traws Pharma (TRAW) EBIAT (2016 - 2025)
Traws Pharma's EBIAT history spans 14 years, with the latest figure at -$7.4 million for Q4 2025.
- Quarterly results put EBIAT at -$7.4 million for Q4 2025, up 75.13% from a year ago — trailing twelve months through Dec 2025 was $9.2 million (up 105.51% YoY), and the annual figure for FY2025 was $9.2 million, up 105.51%.
- EBIAT for Q4 2025 was -$7.4 million at Traws Pharma, down from -$4.0 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $21.5 million in Q1 2025 to a low of -$123.1 million in Q2 2024.
- The 5-year median for EBIAT is -$4.5 million (2021), against an average of -$10.6 million.
- The sharpest move saw EBIAT tumbled 2797.48% in 2024, then surged 531.27% in 2025.
- Year by year, EBIAT stood at -$3.8 million in 2021, then tumbled by 44.0% to -$5.4 million in 2022, then increased by 22.8% to -$4.2 million in 2023, then crashed by 615.15% to -$29.9 million in 2024, then skyrocketed by 75.13% to -$7.4 million in 2025.
- According to Business Quant data, EBIAT over the past three periods came in at -$7.4 million, -$4.0 million, and -$915000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.